The Week of

London-based biotech EpilepsyGTx announced it raised $33 million in Series A financing.

With backing from XGEN Venture and the British Business Bank, EpilepsyGTx will use this capital to push its lead program, EPY201, into first-in-human Phase 1/2a trials.

EPY201 is an investigational gene therapy designed to treat focal refractory epilepsy – a form of epilepsy where seizures originate from a specific part of the brain and fail to respond to standard medications.

If clinical trials are successful, EPY201 could be transformative for the roughly 10 million patients worldwide living with seizures that don’t respond to existing drugs. Here’s more: https://www.epilepsygtx.com/news/epilepsygtx-raises-33-million-series-a-to-develop-single-dose-gene-therapy-for-focal-refractory-epilepsy/

Biogen and Stoke Therapeutics unveiled encouraging clinical data showing that zorevunersen, an investigational therapy designed to treat a rare and severe genetic form of epilepsy called Dravet syndrome, significantly reduces seizures in Dravet syndrome patients.

Analysts at Jefferies are now projecting blockbuster potential for the treatment, with peak sales estimates in the $1 billion to $4 billion range for a therapy that goes beyond standard anti-seizure medicines.

The data also suggest improvements in cognition and behavior, hinting that zorevunersen might do more than just suppress seizures, but potentially modify the course of disease. Check it out: https://www.biospace.com/drug-development/biogen-stoke-boost-epilepsy-drugs-blockbuster-potential-with-early-seizure-reduction-data

New research published in the journal Biomedical Signal Processing and Control, has shown that deep learning can use EEG signals to distinguish Alzheimer’s disease from frontotemporal dementia with high accuracy. 

The system also estimated disease severity, offering clinicians faster insight than traditional tools. These findings suggest that affordable EEG technology, paired with advanced AI, may streamline diagnosis and personalize care for people experiencing cognitive decline. Here’s more: https://www.sciencedirect.com/science/article/abs/pii/S1746809425011784?via%3Dihub

Did you know that three New Jersey hospitals could soon receive state funding to research the medicinal benefits of psilocybin to treat mental health disorders?

State lawmakers are actively pushing legislation that would create a two-year pilot program in which the drug would be administered at the hospitals. Patients’ experiences being monitored under strict medical supervision.

The research and information gathered from these clinical trials at the hospitals would then be used by state leaders to determine whether New Jersey should create a “psilocybin care delivery system,” allowing access to the drug for residents suffering from acute mental health disorders. Here’s more: https://newjerseymonitor.com/2025/11/25/nj-bill-legalize-psychedelic-mushrooms/